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Application of mild hyperthermia can increase the cytotoxicity of anticancer drugs in tumour cells. In this
report, we describe low molecular weight thermoactive ruthenium-based drugs with ﬂuorous chains that
are selectively triggered by mild hyperthermia. The organometallic complexes were prepared,
characterized, and evaluated for their in vitro cytotoxicity against a panel of human cancer cell lines and
non-cancerous immortalized cells. The compounds show considerable chemo-thermal selectivity towards
cancer cells (ca. 5 mM versus >500 mM for healthy cells) for the compound with the longest ﬂuorous chain.Introduction
Platinum-based anticancer drugs including cisplatin, carbo-
platin and oxaliplatin lack selectivity towards cancerous cells
and therefore their therapeutic application causes severe side-
eﬀects such as nephrotoxicity,1–3 neurotoxicity,4,5 nausea and
vomiting.6,7 In contrast, ruthenium-based chemotherapeutics
present fewer side-eﬀects compared to platinum-based drugs.
Although ruthenium-based compounds are not currently
employed in the clinic, two ruthenium(III) compounds, namely
KP10198 and NAMI-A,9 completed phase I clinical trials and are
currently in phase II trials. The diﬀerent toxicity proles of
platinum- and ruthenium-based compounds remain unclear,
although several reasons have been proposed.10 Irrespective of
the full mechanistic diﬀerences it is not unreasonable that DNA
targeting by platinum compounds leads to the severe side-
eﬀects due to the ubiquitous nature of this target. Interestingly,
organoruthenium (piano-stool) complexes with the structural
composition [RuII(h6-arene)X2(PTA)] (PTA ¼ 1,3,5-triaza-7-
phosphaadamantane), known as RAPTA compounds, exhibit
anti-metastatic11 and anti-angiogenic12 properties coupled
with a relatively low toxicity comparable to that observed
for NAMI-A.13
In an eﬀort to improve drug selectivity it is possible to
enhance the activity of a compound at the tumour site by
applying external techniques or inducers.14 One such strategy
combines chemotherapy with tumour localised mild hyper-
thermia.15–17 A slight increase of the local temperature diﬀer-
entiates tissues, healthy ones adapting easily while cancerous
cells, with a disorganized and compact vascular structure, haveques, Ecole Polytechnique Fe´de´rale de
-mail: paul.dyson@ep.ch
ESI) available: Detailed descriptions of
all compounds, procedures for the
e measurements by ICP-MS. See DOI:
hemistry 2014diﬃculties in dissipating the heat. Some chemotherapeutics
exhibit increased activity under mild hyperthermia (40.5–
42 C),18 even though they are also cytotoxic under normal
conditions, and were not intentionally designed for this appli-
cation. The thermosensitivity of small molecule drugs can be
enhanced by attaching them to thermoresponsive macromole-
cules, e.g. liposomal drug carriers19–24 or micelles that are
insoluble at 37 C and become soluble under hyperthermia,
enabling them to cross the cell membrane where they release
their drug content.25,26 Replacing macromolecules with low
molecular weight thermosensitive drugs remains an attractive
alternative approach. As proof of concept, rationally designed
thermoactive derivatives of the organic drug chlorambucil
(CLB)27,28 have been recently designed and were found to be
essentially inactive at 37 C and activated by mild hyperthermia
(41 C) in vitro.29 Recently, the synthesis and biological evalua-
tion (under normal conditions) of some short to medium length
uorous chain bipyridine cisplatin derivatives have been
reported.30,31 Similar types of compounds (amphiphilic uo-
roalkylated bipyridine platinum and palladium complexes)
have also been tested in liposomal formulations.32–34 Liposomal
formulations of platinum-based drugs, with the rational that
liposomal delivery can increase drug bioavailability and also
accumulation at the tumour site as a consequence of the
enhanced permeability and retention (EPR) eﬀect, are now in
clinical trials.35–38 Herein, ruthenium(II)–arene derivatives
(Fig. 1) modied with uorous chains in order to endow them
with thermoresponsive properties39–41 are described.
The general structure of these new ruthenium(II)–arene
complexes is similar to that of RAPTA-C (Fig. 1) – the PTA ligand
being replaced with the desired uorous or alkyl derivatized
pyridine ligands. The two labile chloride ligands allow activa-
tion via hydrolysis following cellular internalization.11,42 Pyri-
dine was selected as the coordinating moiety based on the
widespread use of such ligands in the domain.43–51 The uorous
and alkyl chains are connected to the pyridine ligand via anChem. Sci., 2014, 5, 1097–1101 | 1097
Fig. 1 Structure of RAPTA-C and the new ruthenium(II)–arene complexes derivatized with alkyl or ﬂuoroalkyl ‘ponytails’.
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View Article Onlineester linker that may, in principle, be hydrolysed by intracellular
enzymes such as esterases.41,52,53Results and discussion
The proposed approach implies a straightforward synthetic
pathway and, consequently, the new derivatives, containing
either an alkyl or uorous chain, were synthesized in two steps
using modied pyridine ligands as shown in Scheme 1. The
pyridine ligands were obtained in good yield (70–87%) using a
standard procedure starting from commercially available 3-pyri-
dine-propionic acid and the corresponding alkyl or uoroalkyl
alcohols. In the second step the pyridine ligands were reacted
with the dimer, [Ru(h6-p-cymene)Cl2]2, in anhydrous, degased
dichloromethane in the dark under an inert atmosphere. The
complexes were isolated by precipitation in good yield (71–87%).
All the compounds have been fully characterized (1H, 13C
and where appropriate 19F NMR spectroscopy, ESI mass spec-
trometry, IR spectroscopy and elemental analysis: see ESI for
details†). The formation of the ester ligands (both alkyl and
peruoroalkyl derivatives) is accompanied by a deshielding of
around 0.4 ppm of the protons in the alpha position relative to
the oxygen atom, and subsequent complexation to the ruthe-
nium center via the pyridine N-atom is accompanied by a
deshielding of ca. 0.4 ppm for the two pyridine protons in the
alpha position to the nitrogen atom and of a deshielding of ca. 5
ppm for the respective carbon atoms. There is only little change
in position of the proton signals of the p-cymene ring in
comparison to those observed in the parent dimer [Ru(h6-p-
cymene)Cl2]2. The structures of the compounds were further
corroborated by ESI-MS. The most abundant peaks observed in
the spectra of the ligands are those assigned to [M + H]+ ions,
whereas the spectra of the pyridine Ru(II)-p-cymene complexes
are dominated by species assigned to [M Cl]+ ions. Apart fromScheme 1 Synthesis of ligands L1a–L2c and the ruthenium-p-cymene c
1098 | Chem. Sci., 2014, 5, 1097–1101the 19F NMR spectra and the very specic 13C NMR prole, the
presence of the uorous chain is also clearly evidenced from the
IR spectra with the presence of a strong large peak between 1110
and 1250 cm1. A peak at ca. 1730 cm1 conrms the presence
of the ester C]O group.In vitro anticancer activity
The cytotoxicity of the modied pyridine ligands and their
corresponding complexes has been assessed in various cancer
cell lines (cisplatin-sensitive A2780 and resistant A2780cisR
ovarian carcinoma, MCF-7 and MDA-MBA-231 breast carci-
nomas and A549 human lung carcinoma) and human embry-
onic kidney (HEK 293) cells (used as a model for normal cells).
Cytotoxicity studies were carried out at 37 C for 72 hours and at
41 C for 2 hours followed by 70 hours at 37 C to simulate
hyperthermia in the tested cell lines (Table 1).
Distinct thermosensitive behaviour of the compounds is
present, but needs to be evident against the majority of the
tested cancerous cell lines in order to be considered as eﬀective.
In this respect, complex 2c exhibits considerable diﬀerences of
up to at least two orders of magnitude (maximum concentra-
tions tested were 500 mM) and hence exhibits ideal thermores-
ponsive behaviour. In all cases, complex 2c remains inactive at
normal body temperature (IC50 values >500 mM) and becomes
toxic towards tumour cells aer a 2 hour hyperthermia signal
(IC50 values ranging from 5.0 to 42 mM in the various cancer cell
lines). Strikingly, the ligand in 2c, i.e. L2c, shows no ther-
moactivity or cytotoxicity against the screened cell lines except
on MCF-7 breast cancer with a negligible (non-thermores-
ponsive) toxicity of 237 mM at 37 C and 284 mM under hyper-
thermia. Moreover, 2c shows selectivity towards cancerous cells
with a weak cytotoxicity under mild hyperthermia against HEK
293 cells.omplexes 1a–2c.
This journal is © The Royal Society of Chemistry 2014
Table 1 IC50 values determined for the ligands L1a–L2c and complexes 1a–1d and 2a–2c in A2780, A2780cisR, A549, MCF-7, MDA-MB-231 and
HEK 293 cell lines at 37 C and under hyperthermia (2 h at 41 C followed by 70 h at 37 C – labeled 41 C in the table)
Compound
A2780 (mM) A2780cisR (mM) MCF-7 (mM) MDA-MB-231 (mM) A549 (mM) HEK 293 (mM)
37 C 41 C 37 C 41 C 37 C 41 C 37 C 41 C 37 C 41 C 37 C 41 C
L1a >500 263  12 >500 389  27 >500 458  16 >500 459  27 303  17 358  20 >500 338  3
L1b >500 98  7 224  23 >500 >500 133  13 >500 >500 >500 323  18 >500 153  12
L1c >500 69  4 69  4 97  15 315  48 110  7 487  9 >500 96  3 100  9 189  10 206  1
L1d >500 40  4 88  5 >500 301  75 >500 >500 >500 >500 >500 >500 >500
L2a >500 181  12 141  9 >500 209  5 136  1.8 362  24 >500 364  8 >500 >500 >500
L2b 476  164 243  35 192  7 >500 >500 >500 >500 >500 >500 >500 >500 >500
L2c >500 >500 >500 >500 237  25 284  31 >500 >500 >500 >500 >500 >500
1a >500 23  1 114  1 482  18 339  73 218  4 328  22 100  2 >500 >500 155  17 324  10
1b >500 49  1 >500 362  14 319  87 108  2 >500 473  20 >500 >500 >500 45  3
1c 113  2 49  1 84  1 48  1 >500 63  4 >500 96  8 391  14 123  8 86  10 42  1
1d >500 15  1 >500 27  1 >500 17  1 70  8 >500 >500 42  12 >500 149  9
2a >500 52  2 111  1 >500 >500 70  4 275  19 67  9 355  43 >500 270  18 160  6
2b 44  1 15  1 25  2 21  1 38  2 25  2 36  2 31  2 43  1 40  2 >500 >500
2c >500 10  1 >500 42  2 >500 5.0  0.3 >500 36  5 >500 33  7 >500 132  5
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View Article OnlineThe incorporation of the uorous chain appears to give rise
to the thermoactive eﬀect. Indeed, complex 1c, the hydrocarbon
analogue of 2c, exhibits a totally diﬀerent prole to 2c. It is
active in some cell lines at 37 C and also moderately toxic
against non-tumourigenic HEK 293 cells with an IC50 value of 86
mM. Complexes with shorter alkyl chains, i.e. 1a and 1b, show
generally poor activity against cancerous and non-cancerous
cells. Complex 1d, with the longest alkyl chain, exhibits good
thermoactivity except in the MDA-MB-231 cell line with an IC50
of 70 mM at 37 C and >500 mM under hyperthermia. Similarly,
its ligand alone, L1d, is only thermoactive in A2780 cells.
Indeed, against A2780cisR and MCF-7 cells, L1d is more active
than the corresponding complex at normal body temperature,
but loses activity under hyperthermia, a behaviour shared with
ligands L1b, L2a, L2b and even complex 2a.
Excluding the cisplatin-resistant cell line, only L2a is less
cytotoxic under hyperthermia against MDA-MB-231 and A459
cells. Ligands L1d and L2b are inactive at both temperatures in
the other cell lines. Ligands with the longest, bulky chains, i.e.
L2b, L2c and L1d, are the least active ligands across the panel of
cell lines. In A2780 cells the alkylated ligands show increasing
cytotoxicity under hyperthermia as the chain length increases,
possibly due to increased lipophilicity.
Compounds containing the shorter uorinated chains do
not exhibit a thermoactivity comparable to 2c. Consequently,
the length of the uorous chain has a signicant impact on the
potential thermoactive behaviour, which is consistent with the
results from the study of chlorambucil modied with uorinated
chains.29 Nevertheless, 2b is remarkably cytotoxic and selective
towards cancerous cells compared to normal cells, whereas the
activity of 2a is not aﬀected by mild hyperthermia in a systematic
manner, presumably due to the short uorous chain.Fig. 2 Cellular uptake of 2c in A2780 and HEK 293 cell lines with and
without a 2 hour hyperthermia signal at 41 C. Error bars represent
Standard Deviation.Cellular uptake
Cellular uptake studies were conducted on the lead complex, i.e.
2c, to determine the dependency of uptake on temperature in
cancerous and non-cancerous cells. A 2 hour heating at 41 CThis journal is © The Royal Society of Chemistry 2014was used to simulate the hyperthermia signal during a 24 hour
incubation prior to measurement. At 37 C 2c is internalized
three fold more in the A2780 ovarian cancer cell line compared
to the normal HEK 293 cells (Fig. 2). Under mild hyperthermia,
internalization of 2c in A2780 cells increases whereas heat has
little impact on uptake into HEK 293 cells. These data are
consistent with the tumour cell selectivity observed for 2c. It
should be noted, however, that while uptake of 2c into cancer
cells exceeds that in the HEK 293 cells, uptake alone does not
explain the vast diﬀerences in cytotoxicity following heat treat-
ment. In this context the diﬃculties cancer cells have dissi-
pating heat54,55 must also make them more susceptible to cell
death induced by the internalized compound.Chem. Sci., 2014, 5, 1097–1101 | 1099
Chemical Science Edge Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
2 
Ja
nu
ar
y 
20
14
. D
ow
nl
oa
de
d 
on
 5
/8
/2
01
9 
5:
16
:3
7 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article OnlineConclusions
Organometallic ruthenium complexes with a long uorous
appendage exert selective cytotoxicity toward tumour cells
under mild hyperthermia. Long uorous chains are required to
obtain relevant thermoresponsive behaviour. For the lead
compound, i.e. 2c, it is noteworthy that the uorous ligand
alone is not cytotoxic under any of the applied conditions
whereas the ruthenium complex demonstrates considerable
diﬀerences under normal and thermal conditions (ca. 5 mM
versus >500 mM) and selectivity towards cancer cells over healthy
HEK 293 cells. Discrimination between cancerous and normal
cells may be attributed to more extensive internalization by
cancer cells compared to normal cells combined with the fact
that the tumoural cells are sensitized to the cytotoxic agents
under mild hypothermia. This discovery opens the way towards
the rational design of other thermoactive anticancer drugs.
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